Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The clinical evidence for tafasitamab with lenalidomide is derived from a small, single-arm Phase 2 study (L-MIND) with 81 participants, which did not directly compare the treatment to standard options. While the study showed promising results with a 58% objective response rate and median overall survival of 33.5 months, the lack of direct comparisons and the uncertainty surrounding the survival estimates from indirect comparisons limit the robustness of the evidence.
Cost effectiveness
The cost-effectiveness estimates for tafasitamab with lenalidomide were found to be above the range that NICE typically considers acceptable for end-of-life treatments. The committee concluded that the treatment was not cost-effective based on the presented ICERs, which were deemed highly uncertain and not plausible.
Quality of life
The document indicates that any treatment that can be administered in an outpatient setting would significantly improve the quality of life for patients with relapsed or refractory diffuse large B-cell lymphoma. However, specific HRQoL data or validated instruments measuring these improvements were not provided, leading to a rating of B+ due to the absence of direct evidence.
Supporting Domains
Safety and Adverse Effects
The safety profile of tafasitamab with lenalidomide was not extensively detailed in the document, but it was noted that the treatment is expected to be more tolerable than existing options. The committee acknowledged the potential for serious side effects associated with current treatments, suggesting that tafasitamab may offer an acceptable safety profile.
Comparator Selection
The company selected relevant comparators, including polatuzumab vedotin with bendamustine and rituximab, which is considered standard care. The committee agreed that the choice of comparators was appropriate, although the submission did not include all potential comparators outlined in the NICE scope.
Patient Population and Subgroups
The trial population in the L-MIND study was relatively small and not fully representative of the broader patient population with relapsed or refractory diffuse large B-cell lymphoma. While the study included patients who could not undergo autologous stem cell transplant, there were notable differences in baseline characteristics compared to real-world data, leading to concerns about generalizability.
Care Pathway Integration
The treatment can be administered in an outpatient setting, which aligns well with current clinical practices. This suggests a good fit within existing care pathways, although some adjustments may be necessary for implementation.
Resource Use and Cost Implications
The document indicates that the cost implications of tafasitamab with lenalidomide are significant, with high treatment costs that raise concerns about budget impact. The committee noted that the treatment’s cost-effectiveness was not demonstrated, which could lead to resource burden.
Evidence Quality and Robustness
The evidence base is primarily derived from a single-arm Phase 2 study, which introduces limitations in terms of robustness and potential biases. The committee highlighted the need for more comprehensive data to support the findings, particularly regarding indirect comparisons.
Uncertainty, Sensitivity, and Broader Impacts
There is considerable uncertainty surrounding the treatment’s effectiveness and cost-effectiveness due to the reliance on indirect comparisons and the lack of robust survival data. The committee noted that while there is a high unmet need, the uncertainties present significant challenges for decision-making.
